MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

NewsGuard 100/100 Score

The Muscular Dystrophy Association today announced funding, totaling $13.7 million, for 40 new research initiatives targeting nearly two dozen progressive neuromuscular diseases.  Among these are 13 new initiatives targeting Duchenne muscular dystrophy (DMD), nine new projects focused on ALS (amyotrophic lateral sclerosis or Lou Gehrig's disease), as well as efforts on spinal muscular atrophy (SMA), facioscapulohumeral muscular dystrophy (FSHD), and the link between diabetes and Friedreich's ataxia (FA).

These new projects are in addition to hundreds of other MDA-funded scientific investigations being advanced worldwide to find effective treatments for neuromuscular diseases.  

"Truly rapid progress is being made in the fight against muscular dystrophy, ALS and related diseases," said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors.  "And MDA will not stop until these diseases are conquered."

This latest round of peer-reviewed grants recommended by the Association's Medical and Scientific Advisory Committees comprising the world's top medical and scientific authorities was approved for funding by the MDA Board of Directors. The promising new initiatives are underway in 17 U.S. cities, the District of Columbia, as well as in Australia, Canada, Costa Rica, Italy, the Netherlands and the United Kingdom:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings